CN114787156B - 新颖甲基喹唑啉酮衍生物 - Google Patents

新颖甲基喹唑啉酮衍生物 Download PDF

Info

Publication number
CN114787156B
CN114787156B CN202080084994.3A CN202080084994A CN114787156B CN 114787156 B CN114787156 B CN 114787156B CN 202080084994 A CN202080084994 A CN 202080084994A CN 114787156 B CN114787156 B CN 114787156B
Authority
CN
China
Prior art keywords
compound
formula
cancer
braf
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080084994.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114787156A (zh
Inventor
C·多伦特
D·S·休温斯
D·霍恩奇克
D·克鲁门纳赫
P·F·T·佩塔佐尼
J·维希曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN202410878222.7A priority Critical patent/CN118791472A/zh
Publication of CN114787156A publication Critical patent/CN114787156A/zh
Application granted granted Critical
Publication of CN114787156B publication Critical patent/CN114787156B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Combines (AREA)
  • Harvester Elements (AREA)
CN202080084994.3A 2019-12-10 2020-12-08 新颖甲基喹唑啉酮衍生物 Active CN114787156B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410878222.7A CN118791472A (zh) 2019-12-10 2020-12-08 新颖甲基喹唑啉酮衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214941.7 2019-12-10
EP19214941 2019-12-10
PCT/EP2020/084976 WO2021116055A1 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410878222.7A Division CN118791472A (zh) 2019-12-10 2020-12-08 新颖甲基喹唑啉酮衍生物

Publications (2)

Publication Number Publication Date
CN114787156A CN114787156A (zh) 2022-07-22
CN114787156B true CN114787156B (zh) 2024-07-26

Family

ID=68848113

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080084994.3A Active CN114787156B (zh) 2019-12-10 2020-12-08 新颖甲基喹唑啉酮衍生物
CN202410878222.7A Pending CN118791472A (zh) 2019-12-10 2020-12-08 新颖甲基喹唑啉酮衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410878222.7A Pending CN118791472A (zh) 2019-12-10 2020-12-08 新颖甲基喹唑啉酮衍生物

Country Status (29)

Country Link
US (2) US12116349B2 (https=)
EP (2) EP4483882A3 (https=)
JP (2) JP7108146B2 (https=)
KR (1) KR102836833B1 (https=)
CN (2) CN114787156B (https=)
AR (1) AR122351A1 (https=)
AU (1) AU2020403443B2 (https=)
CL (1) CL2022001529A1 (https=)
CO (1) CO2022008968A2 (https=)
CR (1) CR20220251A (https=)
DK (1) DK4073065T3 (https=)
ES (1) ES3023264T3 (https=)
FI (1) FI4073065T3 (https=)
HR (1) HRP20250418T1 (https=)
HU (1) HUE071148T2 (https=)
IL (2) IL316473A (https=)
LT (1) LT4073065T (https=)
MA (1) MA58087B1 (https=)
MX (1) MX2022006783A (https=)
PE (1) PE20221778A1 (https=)
PH (1) PH12022551119A1 (https=)
PL (1) PL4073065T3 (https=)
PT (1) PT4073065T (https=)
RS (1) RS66721B1 (https=)
SI (1) SI4073065T1 (https=)
TW (2) TWI877268B (https=)
UA (1) UA128299C2 (https=)
WO (1) WO2021116055A1 (https=)
ZA (2) ZA202204675B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020403082A1 (en) * 2019-12-10 2022-05-12 F. Hoffmann-La Roche Ag New BRAF inhibitors as paradox breakers
PH12022551119A1 (en) 2019-12-10 2023-08-23 Hoffmann La Roche New methylquinazolinone derivatives
TW202426436A (zh) 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和病症之化合物
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
IL307964A (en) * 2021-06-09 2023-12-01 Chugai Pharmaceutical Co Ltd Combined treatment for cancer
CA3216220A1 (en) * 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
MX2023014629A (es) * 2021-06-09 2024-01-30 Hoffmann La Roche Nuevas formas solidas de (3r)-n-[2-ciano-4-fluoro-3-(3-metil-4-oxo -quinazolin-6-il)oxi-fenil]-3-fluoro-pirrolidin-1-sulfonamida.
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4426305A1 (en) 2021-11-04 2024-09-11 F. Hoffmann-La Roche AG Novel use of quinazolinone compound for the treatment of cancer
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
EP4618994A1 (en) 2022-11-18 2025-09-24 F. Hoffmann-La Roche AG Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
WO2024126660A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
TW202438072A (zh) * 2022-12-15 2024-10-01 瑞士商赫孚孟拉羅股份公司 製備喹唑啉酮衍生物之方法
KR20260032991A (ko) 2023-07-04 2026-03-10 에프. 호프만-라 로슈 아게 (3r)-n-[2-시아노-4-플루오로-3-(3-메틸-4-옥소-퀴나졸린-6-일)옥시-페닐]-3-플루오로-피롤리딘-1-설폰아미드의신규 고체 형태
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
TW202545530A (zh) * 2024-01-17 2025-12-01 大陸商海思科醫藥集團股份有限公司 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用
WO2026037755A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives
WO2026046946A1 (en) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3147281A1 (en) 2008-03-17 2017-03-29 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
AU2013318283A1 (en) 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
US9814714B2 (en) 2015-05-22 2017-11-14 Plexxikon Inc. Kinase modulation, and indications therefor
RU2724345C2 (ru) 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
AU2020403082A1 (en) * 2019-12-10 2022-05-12 F. Hoffmann-La Roche Ag New BRAF inhibitors as paradox breakers
PH12022551119A1 (en) 2019-12-10 2023-08-23 Hoffmann La Roche New methylquinazolinone derivatives
TW202426436A (zh) 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和病症之化合物
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
JP2023554062A (ja) 2020-12-18 2023-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規アリール－ピリド－ピリミジン－オン誘導体
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
US20250011304A1 (en) 2021-12-08 2025-01-09 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600E kinase;Steve Wenglowsky et al.;《Bioorganic & Medicinal Chemistry Letters》;第24卷;1923-1927 *

Also Published As

Publication number Publication date
UA128299C2 (uk) 2024-05-29
JP7108146B2 (ja) 2022-07-27
BR112022011123A2 (pt) 2022-08-23
EP4483882A2 (en) 2025-01-01
FI4073065T3 (fi) 2025-04-16
KR102836833B1 (ko) 2025-07-22
SI4073065T1 (sl) 2025-06-30
PL4073065T3 (pl) 2025-05-19
PT4073065T (pt) 2025-04-15
JP2022531609A (ja) 2022-07-07
AR122351A1 (es) 2022-09-07
US20240174621A1 (en) 2024-05-30
MA58087B1 (fr) 2025-04-30
DK4073065T3 (da) 2025-04-22
PH12022551119A1 (en) 2023-08-23
WO2021116055A1 (en) 2021-06-17
JP2022124458A (ja) 2022-08-25
RS66721B1 (sr) 2025-05-30
TWI877268B (zh) 2025-03-21
US20220298119A1 (en) 2022-09-22
AU2020403443A1 (en) 2022-05-12
CA3162883A1 (en) 2021-06-17
HRP20250418T1 (hr) 2025-06-06
CN118791472A (zh) 2024-10-18
PE20221778A1 (es) 2022-11-16
CL2022001529A1 (es) 2023-02-10
JP7802514B2 (ja) 2026-01-20
TWI908405B (zh) 2025-12-11
CN114787156A (zh) 2022-07-22
ZA202204675B (en) 2022-12-21
IL316473A (en) 2024-12-01
TW202504895A (zh) 2025-02-01
AU2020403443B2 (en) 2023-02-23
KR20220110554A (ko) 2022-08-08
CO2022008968A2 (es) 2022-07-19
US12116349B2 (en) 2024-10-15
EP4073065B1 (en) 2025-02-19
LT4073065T (lt) 2025-04-25
MX2022006783A (es) 2022-07-11
EP4073065A1 (en) 2022-10-19
TW202136245A (zh) 2021-10-01
CR20220251A (es) 2022-07-11
ZA202206923B (en) 2024-10-30
ES3023264T3 (en) 2025-05-30
IL292161B2 (en) 2025-04-01
NZ787393A (en) 2025-07-25
IL292161B1 (en) 2024-12-01
HUE071148T2 (hu) 2025-08-28
IL292161A (en) 2022-06-01
EP4483882A3 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
CN114787156B (zh) 新颖甲基喹唑啉酮衍生物
CN113966335B (zh) 用于治疗癌症的egfr抑制剂
CN113993590B (zh) 新型egfr抑制剂
US20240139192A1 (en) Methods and compositions comprising a braf inhibitor and a mek inhibitor
JP7737991B2 (ja) Ｅｇｆｒ阻害剤
CA3162883C (en) (3r)-and (3s)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide compounds and their use as braf inhibitors
RU2802968C1 (ru) Новые производные метилхиназолинона
HK40074142A (en) New methylquinazolinone derivatives
HK40113036A (zh) 新颖甲基喹唑啉酮衍生物
HK40074142B (zh) 新颖甲基喹唑啉酮衍生物
BR112022011123B1 (pt) Composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto
RU2818677C2 (ru) Ингибитор egfr для лечения рака
BR122024014190A2 (pt) Combinação, uso de um inibidor de braf e um inibidor de mek, composições farmacêuticas e uso da composição farmacêutica
HK40079554A (en) Egfr inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074142

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant